Electronic and structural aspects of P450-mediated drug metabolism

Drug Metabolism Letters

Volumn 3, Issue 2, 2009, Pages 87-100

  Lewis, David F V ^a   Ito, Yuko ^b   Lake, Brian G ^a,c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

^c LFI Molecular Sciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; 7 ETHOXYCOUMARIN; AMFEBUTAMONE; AMODIAQUINE; BUFURALOL; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEBRISOQUINE; DIAZEPAM; DICLOFENAC; FLURBIPROFEN; MEPHENYTOIN; NICOTINE; OCTANOL; OMEPRAZOLE; PHENACETIN; PROGESTERONE; TROGLITAZONE; UNINDEXED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ELECTRON TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HUMAN; INTERMETHOD COMPARISON; IONIZATION; LIPOPHILICITY; LIVER MICROSOME; METABOLIC CLEARANCE RATE; OXIDATION REDUCTION POTENTIAL; PARTITION COEFFICIENT; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MODELS, MOLECULAR; MODELS, THEORETICAL; OCTANOLS; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 69949085177     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231209788654090     Document Type: Article

References (100)

1. Archakov, A.I.; Bachmanova, G.I. Cytochrome P450 and Active Oxygen; Taylor & Francis: London, 1990.
2. Lewis, D.F.V. Guide to Cytochrome P450 Structure and Function, Taylor & Francis: London, 2001.
3. Lewis, D.F.V. Cytochromes P450: Structure, Function and Mechanism, Taylor & Francis, London, 1996.
4. Guengerich, F.P. In Cytochrome P450 P.R. Ortiz de Montellano, Ed.; Kluwer/Plenum: New York, 2005, 377-530.
5. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Met. Rev., 2002, 34, 83-448.
6. Smith, D.A.; Ackland, M.J.; Jones, B.C. Properties of cytochrome P450 isozymes and their substrates Part 2: properties of cytochrome P450 substrate. Drug Disc. Today, 1997, 2, 479-486.
7. Smith, D.A.; Ackland, M.J.; Jones, B.C. Properties of cytochrome P450 isozymes and their substrates Part 1: active site characteristics. Drug Disc. Today, 1997, 2, 406-414.
8. Bertz, R.J.; Granneman, G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinetics, 1997, 32, 210-258.
9. Houston, J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharma., 1994, 47, 1469-1479.
10. Houston, J.B.; Galetin, A. Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Met. Rev., 2003, 35, 393-415.
11. Ito, K.; Houston, J.B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharma. Res., 2005, 22, 103-112.
12. Iwatsubo, T.; Hirota, N.; Ooie, T.; Suzuki, H.; Shimada, N.; Chiba, K.; Ishizaki, T.; Green, C.E.; Tyson, C.A.; Sugiyama, Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharma. Therap., 1997, 73, 147-171.
13. Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, M.; Jones, B.C.; MacIntyre, F.; Rance, D.J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharma. Exp. Therap., 1997, 283, 46-58.
14. Afzelius, L.; Hasselgren Arnby, C.; Broo, A.; Carlsson, L.; Isaksson, C.; Jurva, U.; Kjellander, B.; Kolmodin, K.; Nilsson, K.; Raubacher, F.; Weidolf, L. State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights and future applications. Drug Met. Rev., 2007, 39, 61-86.
15. Brown, H.S.; Griffin, M.; Houston, J.B. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Met. Dispos., 2007, 35, 293-301.
16. Hidestrand, M.; Oscarson, M.; Salonen, J.S.; Nyman, L.; Pelkonen, O.; Turpeinen, M.; Ingelman-Sundberg, M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Met. Dispos., 2001, 29, 1480-1484.
17. Lin, Y.; Lu, P.; Tang, C.; Mei, Q.; Sandig, G.; Rodrigues, A.D.; Rushmore, T.H.; Shou, M. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Met. Dispos., 2001, 29, 368-374.
18. Easterbrook, J.; Fackett, D.; Li, A.P. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenacetin O-deethylation, coumarin 7hydroxylation, tolbutamide 4-hydroyxlation, S-mephenytoin 4′hydroxylation, chlorzoxazone 6-hydroxylation and testosterone 6βhydroxylation. Chemico-Bio. Interactions, 2001, 134, 243-249.
19. Ha, H.R.; Chen, J.; Krahenbuhl, S.; Follath, F. Biotransformation of caffeine by cDNA-expressed human cytochromes P450. Eur. J. Clin. Pharma., 1996, 49, 309-315.
20. Yuan, R.; Madani, S.; Wei, X.-X.; Reynolds, K; Huang, S.-M. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Met. Dispos., 2002, 30, 1311-1319.
21. Galetin, A.; Brown, C.; Hallifax, D.; Ito, K.; Houston, J.B. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5 and CYP2C19 on CYP3A4 probe substrates. Drug Met. Dispos., 2004, 32, 1411-1420.
22. Griffin, S.J.; Houston, J.B. Prediction of in vitro intrinsic clearance from hepatocytes: comparson of suspensions and monolayer cultures. Drug Met. Dispos., 2005, 33, 115-120.
23. Hanioka, N.; Tanaka-Kagawa, T.; Miyata, Y.; Matsushima, E.; Makino, Y.; Ohno, A.; Yoda, R.; Jinno, H.; Ando, M. Functional characterization of three human cytochrome P450 2E1 variants with amino acid substitutions. Xenobiotica, 2003, 33, 575-586.
24. Ekins, S.; Ring, B.J.; Binkley, S.N.; Hall, S.D.; Wrighton, S.A. Autoactivation and activation of the cytochrome P450s. Int. J. Clin. Pharma. Therap., 1998, 36, 642-651.
25. Faucette, S.R.; Hawke, R.L.; LeCluyse, E.L.; Shord, S.S.; Yan, B; Laetham, R.M.; Lindley, C.M. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Met. Dispos., 2000, 28, 1222-1230.
26. Hallifax, D.; Rawden, H.C.; Hakooz, N.; Houston, J.B. Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Met. Dispos., 2005, 33, 1852-1858.
27. Masimirembwa, C.M.; Otter, C.; Berg, M.; Jönsson, M.; Leidvik, B.; Jonsson, E.; Johansson, T.; Bäckman, A.; Edlund, A.; Andersson, T.B. Heterologous expression and kinetic characterization of human cytochromes P450: validation of a pharmaceutical tool for drug metabolism research. Drug Met. Dispos., 1999, 27, 1117-1122.
28. McGinnity, D.F.; Griffin, S.J.; Moody, G.C.; Voice, M., Hanlon, S.; Friedberg, T.; Riley, R.J. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P450 enzymes expressed in Escherichia coli. Drug Met. Dispos., 1999, 27, 1017-1023.
29. Code, E.L.; Crespi, C.L.; Penman, B.W.; Gonzalez, F.J.; Chang, T.K.H.; Waxman, D.J. Human cytochrome P450 2B6. Drug Met. Dispos., 1997, 25, 985-993.
30. Lightfoot, T.; Ellis, S.W.; Mahling, J.; Ackland, M.J.; Blaney, F.E.; Bijloo, G.J.; de Groot, M.J.; Vermeulen, N.P.E.; Blackburn, G.M.; Lennard, M.S.; Tucker, G.T. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling. Xenobiotica, 2000, 30, 219-233.
31. Li, X.-Q.; Björkman, A.; Andersson, T.B.; Ridderström, M; Masimirembwa, C.M. Amodiaquine clearance and its metabolism to N-desmethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharma. Exp. Therap., 2002, 300, 399-407.
32. Ono, S.; Tsutsui, M.; Gonzalez, F.J.; Satoh, T.; Masubuchi, Y; Horie, T.; Suzuki, T.; Narimatsu, S. Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogen., 1995, 5, 97-102.
33. Walker, D.K.; Alabaster, C.T.; Congrave, G.S.; Hargreaves, M.B.; Hyland, R.; Jones, B.C.; Reed, L.J.; Smith, D.A. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. Drug Met. Dispos., 1996, 24, 447-455.
34. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Exp. Purification, 2002, 24, 329-337.
35. Andrews, J.; Abd-Ellah, M.F.; Randolph, N.L.; Kenworthy, K.E.; Carlile, D.J.; Friedberg, T.; Houston, J.B. Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica, 2002, 32, 937-947.
36. Ekins, S.; Obach, R.S. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. J. Pharma. Exp. Theraps., 2000, 295, 463-473.
37. Higgins, L.; Korzekwa, K.R.; Rao, S.; Shou, M.; Jones, J.P. An assessment of the reaction energetics for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Met. Dispos., 2001, 30, 831-837.
38. Higgins, L.; Korzekwa, K.R.; Rao, S.; Shou, M.; Jones, J.P. An assessment of the reaction energetics for cytochrome P450-mediated reactions. Archives Biochem. Biophysics, 2001, 385, 220-230.
39. Obach, R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non specific binding to microsome. Drug Met. Dispos., 1999, 27, 1350-1359.
40. Obach, R.S. The prediction of human clearance from hepatic microsomal metabolism data. Curr. Opin. Drug Disc. Develop., 2001, 4, 36-44.
41. Obach, R.S.; Reed-Hagen, A.E. Measurement of Michaelis constant for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Met. Dispos., 2002, 30, 831-837.
42. Obach, R.S. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Drug Met. Dispos., 1997, 25, 1359-1369.
43. Lavé, T.; Dupin, S.; Schmitt, C.; Valles, B.; Ubeaud, G.; Chou, R.C.; Jaeck, D.; Coassolo P. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharma. Res., 1997, 14, 152-155.
44. Lavé, T.; Dupin, S.; Schmitt, C.; Chou, R.C.; Jaeck, D.; Coassolo, P. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. Pharma. Sci., 1997, 86, 584-590.
45. Wilkinson, G.R.; Shand, D.G. A physiological approach to hepatic drug clearance. Clin. Pharma. Therap., 1975, 18, 377-390.
46. Thummel, K.E.; Shen, D.D. In: Goodman F Gilman's The Pharmacological Basis Therapeutics, 10th editor, J.G. Hardman, L.E. Limbird and A.G. Gilman, Eds; McGraw-Hill: New York, 2001, 1928-2019.
47. Carlile, D.J.; Hakooz, N.; Bayliss, M.K.; Houston, J.B. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br. J. Clin. Pharma., 1999, 47, 625-635.
48. Smith, D.A.; Jones, B.C.; Walker, D.K. Design of drugs involved in concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev., 1996, 16, 245-266.
49. Jencks, W.P. Binding energy, specificity and enzyme catalysis: the Circe effect. Adv. Enz., 1975, 43, 219-410.
50. Ferscht, A. Enzyme Structure Mechanism, 3rd ed.; Freeman: New York, 1985.
51. Bowman, W.C.; Rand, M.J. Textbook Pharmacology, 2nd ed.; Blackwell: Oxford, 1988.
52. Palmer, T. Understanding Enzymes, 3rd ed.; Ellis Horwood: Chichester, 1991.
53. Kraut, J. How do enzymes work? Science, 1988, 242, 533-540.
54. Lehninger, A.L.; Nelson, D.L.; Cox, M.M. Pr. Biochem., 2nd ed.; Worth: New York, 1993.
55. m and V/K in enzyme kinetics, J. Chem. Edu., 1998, 75, 1153-1157.
56. Clark, B.; Smith, D.A. An Introduction to Pharmacokinetics, 2nd ed.; Blackwell: Oxford, 2001.
57. Hansch, C.; Zhang, L. Quantitative structure-activity relationships of cytochrome P450. Drug Met. Rev., 1993, 25, 1-48.
58. Hansch, C.; Mekapati, S.B.; Kurup, A.; Verma, R.P. QSAR of cytochrome P450. Drug Met. Rev., 2004, 36, 105-156.
59. m. Drug Met. Rev., 1996, 28, 513-526.
60. o values - possible implications in chemotherapy and biotechnology. Biochem. Pharma., 2001, 61, 1049-1055.
61. Plant, A.L.; Pownall, H.J.; Smith, L.C. Transfer of polycyclic aromatic hydrocarbons between model membranes: relation to carcinogenicity. Chemico-Biol. Int., 1983, 44, 237-246.
62. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR: Hydrophobic, Electronic Steric Constants; ACS: Washington, 1995.
63. Dollery, C. Therapeutic Drugs; Churchill-Livingstone: Edinburgh, 1999.
64. Lewis, D.F.V.; Pratt, J.M. The cytochrome P450 catalytic cycle and mechanism of oxygenation. Drug Met. Rev., 1998, 30, 739-786.
65. Lewis, D.F.V.; Hlavica, P. Interactions between redox partners in various cytochrome P450 systems: functional and structural aspects. Biochimica et Biophysica Acta, 2000, 1460, 353-374.
66. Blanck, J.; Rein, H.; Sommer, M.; Ristau, O.; Smettan, G.; Ruckpaul, K. Correlations between spin equilibrium shift, reduction rate and N-demethylation activity in liver microsomal cytochrome P450 and a series of benzphetamine analogues as substrates. Biochem. Pharma., 1983, 32, 1683-1688.
67. Schwartz, W.; Blanck, J.; Ristau, O.; Janig, G.R.; Pommerening, K.; Rein, H.; Ruckpaul, K. Spin state control of cytochrome P450 reduction and catalytic activity in a reconstituted P450 LM2 system as induced by a series of benzphetamine analogues. Chemico-Bio. Int., 1985, 54, 127-141.
68. Petzold, D.R.; Rein, H.; Schwarz, D.; Sommer, M.; Ruckpaul, K. Relation between the structure of benzphetamine analogues and their binding properties to cytochrome P450 LM2. Biochimica et Biophysica Acta, 1985, 829, 253-261.
69. Marcus, R.A.; Sutin, N. Electron transfers in chemistry and biology. Biochimica et Biophysica Acta, 1985, 811, 265-322.
70. Moser, C.C.; Dutton, P.L. Engineering protein structure for electron transfer function in photosynthetic reaction centers, Biochimica et Biophysica Acta. 1992, 110, 171-176.
71. Hazzard, J.T.; Govindaraij, S.; Poulos, T.L.; Tollin, G. Electron transfer between the FMN and heme domains of cytochrome P450BM3. J. Bio. Chem., 1997, 272, 7922-7926.
72. Imai, Y.; Sato, R.; Iyanagi, T. Rate-limiting step in the reconstituted microsomal drug hydroxylase system. J. Biochem., 1977, 82, 1237-1246.
73. Munro, A.W.; Daff, S.; Coggins, J.R.; Lindsay, J.G.; Chapman, S.K. Probing electron transfer in flavocytochrome P450BM3 and its component domains. Eur. J. Biochem., 1996, 239, 403-409.
74. Noble, M.A.; Miles, C.S.; Chapman, S.K.; Lysek, D.A.; MacKay, A.C.; Reid, G.A.; Hanzlik, R.P.; Munro, A.W. Roles of key active site residues in flavocytochrome P450BM3. Biochem. J., 1999, 339, 371-379.
75. Ruckpaul, K.; Rein, K. Cytochrome P450; Akademie-Verlag: Berlin, 1984.
76. Drago, R.S. Physical Methods Inorganic Chemistry; Van Nostrand Reinhold, New York, 1965.
77. Fleming, I. Frontier Orbitals and Organic Chemical Reactions, Wiley: New York, 1980.
78. Fowler, S.M.; Riley, R.J.; Pritchard, M.P.; Sutcliffe, M.J.; Friedberg, T.; Wolf, C.R. Amino acid 305 determines catalytic centre accessibility in CYP3A4. Biochem., 2000, 39, 4406-4414.
79. Lewis, D.F.V. Frontier orbitals in chemical and biological activity: quantitative relationships and mechanistic implications. Drug Met. Rev., 1999, 31, 755-814.
80. Lewis, D.F.V. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem. Pharma., 2000, 60, 293-306.
81. Lewis, D.F.V. Quantitative structure-activity relationships (QSARs) in substrates, inhibitors and inducers of mammalian cytochromes P450. Toxicol., 2000, 144, 197-203.
82. D values). Curr. Drug Met., 2003, 4, 331-340.
83. Lewis, D.F.V. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. Inflammopharma., 2003, 11, 43-73.
84. Lewis, D.F.V. Quantitative structure-activity relationships (QSARs) within human cytochromes P450 substrates of the CYP2 family. Tox. Vit., 2004, 18, 89-97.
85. Lewis, D.F.V.; Dickins, M. Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Met. Rev., 2003, 35, 1-18.
86. Lewis, D.F.V.; Eddershaw, P.J.; Dickins, M.; Tarbit, M.H.; Goldfarb, P.S. Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chemico-Bio. Int., 1998, 115, 175-199.
87. Gunsalus, I.C.; Mercks, J.R.; Lipscomb, J.D.; Debrunner, P.G.; Munch, E. In: Molecular Mechanisms Oxygen Activation; O. Hayaishi, Ed. Academic Press: New York, 1974; 559-613.
88. cam: theory supports a two-state rebound mechanism. J. Am. Chem. Soc., 2004, 126, 4017-4034.
89. Veitch, N.C.; Williams, R.J.P. The molecular basis of electronic transfer in redox enzyme systems. Front. Biotrans., 1992, 7, 279-320.
90. Lewis, D.F.V.; Jacobs, M.N.; Dickins, M. The importance of compound lipophilicity for substrate binding to human P450s involved in drug metabolism. Drug Dis. Today, 2004, 9, 530-537.
91. Rodrigues, A.D. Integrated cytochrome P450 reaction phenotyping, Biochem. Pharma., 1999, 57, 465-480.
92. Barter, Z.E.; Bayliss, M.K.; Beaune, P.H.; Boobis, A.R.; Carlile, D.J.; Edwards, R.J.; Houston, J.B.; Lake, B.G.; Lipscomb, J.C.; Pelkonen, O.; Tucker, G.T.; Rostami-Kodjegan, A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Met., 2007, 8, 33-45.
93. Hakooz, N.; Ito, K.; Rawden, H.; Gill, H.; Lemmers, L.; Boobis, A.R.; Edwards, R.J.; Carlile, D.J.; Lake, B.G.; Houston, J.B. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm. Res., 2006, 23, 533-539.
94. Emoto, C.; Murase, S.; Iwasaki, K. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica, 2006, 36, 671-683.
95. Morris, G.M.; Goodsell, D.S.; Huey, R.; Olson, A.J. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comp. Aid. Mol. Des., 1996, 10, 293-304.
96. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem., 1998, 19, 1639-1662.
97. Bursulaya, B.D.; Abagyam, R.; Brooks, C.L. Comparative study of several algorithms for flexible ligand docking. J. Comp. Aid. Mol. Des., 2003, 17, 755-763.
98. Cruciani, G.; Carosati, E.; De Boeck, B.; Ethirajulu, K.; Mackie, C.; Howe, T.; Vianello, R. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem., 2005, 48, 6970-6979.
99. Guengerich, F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Tox., 2001, 14, 611-650.
100. Lewis, D.F.V. Dickins, M. Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. Toxicology, 2002, 170, 45-53.